Antihyperglycemic Drug

DRUG2 trials

Sponsors

Sanofi

Conditions

DyslipidemiaHypercholesterolaemia

Phase 3

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

CompletedNCT02585778

SanofiHypercholesterolaemia

Start: 2015-10-23End: 2017-04-03Updated: 2018-05-17

Phase 4

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

CompletedNCT02642159

SanofiDyslipidemia

Start: 2016-03-15End: 2017-05-15Updated: 2018-05-01

Related Papers

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Cardiovascular Diabetology2020-02-0831 citations

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.

2019-11-0926 citations

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

2018-03-2364 citations

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial

Diabetes Obesity and Metabolism2017-09-14136 citations

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

2017-05-2517 citations

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

2017-03-2419 citations

PS165 Alirocumab Efficacy is Independent of Background Statin Type or Dose

Global Heart2016-06-01